Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
iMDx Logo
iMDx Growth Score
97
CB Rank
22364
Heat Score
72
iMDx is a biotech company helping save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer.
Founded
obfuscation
PublicPost-IPO Equity Nashville, Tennessee, United States101-250 imdxinc.com/
Biotechnology
Health Care
Hospital
Medical Device
Overview

iMDx
Total Funding
obfuscation
Growth Score
97
Heat Score
72

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score97
2 pts
in past quarter
Heat Score 72
2 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About iMDx

CB Rank
22364
iMDx is a biotech company helping save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer.
Founded
obfuscation
PublicPost-IPO Equity Nashville, Tennessee, United States101-250 imdxinc.com/
Biotechnology
Health Care
Hospital
Medical Device

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

  • Photo of Rob Seitz
    Rob Seitz: Head of Immune Oncology
    Past Role: Insight Genetics, Chief Technology Officer
  • Photo of Josh Riggs
    Josh Riggs: President & Chief Executive Officer
    Past Role: Intelliger Consulting, Founder & Principal

Details

Legal Name Insight Molecular Diagnostics Inc
Also Known As Oncocyte Corporation
Operating Status Active
Stock Symbol  NASDAQ:IMDX
Company Type For Profit
Founders  Karen Chapman
About the Company
iMDx is a molecular diagnostics company that develops and offers blood-based tests for oncology and transplant care. The company offers assays such as GraftAssureCore (a lab test for transplant rejection), GraftAssureIQ (a research-use kit), and DetermaIO for immunotherapy guidance. The company holds CLIA and state lab certifications.
Phone Number +1 615 255 8880
Contact Email info@imdxinc.com
Diversity Spotlight 
Women Founded
Predictions & Insights

Growth Insight

See this Growth Insight
iMDx is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

DetermaCNI
A blood-based test that detects cancer progression early after treatment initiation by measuring cell-free DNA instability.
DetermaIO
A gene expression test that assesses the tumor immune microenvironment to identify patients likely to benefit from immunotherapy.

Research & Development

iMDx is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
1
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
1
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
1
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Bio-Rad Laboratories Logo
Bio-Rad Laboratories
—
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
—
Bio-Rad Laboratories Logo
Bio-Rad Laboratories
—
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
—
Bio-Rad Laboratories Logo
Bio-Rad Laboratories
—
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
—
Bio-Rad Laboratories Logo
Bio-Rad Laboratories
—
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
—
Bio-Rad Laboratories Logo
Bio-Rad Laboratories
—
Post-IPO Equity - iMDx Logo
Post-IPO Equity - iMDx
—

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 7 Contacts 78

Employee Profiles

News

News and Press

News•Jun 29, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 22, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 17, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

839
-41.37%
 in past month

IT Spend

$457.4KThis year, iMDx is projected to spend $457.4K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Epic Games Logo
Epic Games
97
Presto Logo
Presto
96
SAP Logo
SAP
95

Active Website Tech Count

9iMDx is actively using 9 technologies for its website, according to BuiltWith. These include Google Tag Manager, Google Analytics, and  Mobile Non Scaleable Content.
Sub-Organizations

Sub-Organizations

Number of Sub-Orgs 1
Which industries do these Sub-Organization operate in?
Chronix Biomedical Logo
Chronix BiomedicalSubsidiary
Frequently Asked Questions

Where is iMDx's headquarters? iMDx is located in Nashville, Tennessee, United States.Who invested in iMDx? iMDx is funded by Bio-Rad Laboratories.When was the last funding round for iMDx? iMDx closed its last funding round on
obfuscation
from a Post-IPO Equity round.How much funding has iMDx raised to date? iMDx has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(be4ac66 1)
|